See the DrugPatentWatch profile for cosentyx

Based on the information available, there is no definitive evidence to suggest that Cosentyx (secukinumab) directly alters vaccine effectiveness at injection points. However, it is important to note that secukinumab is an immunosuppressant drug, which may affect the immune system's response to vaccines in general [1].

Secukinumab is a monoclonal antibody that binds to interleukin-17A (IL-17A), a cytokine involved in the inflammatory response. By inhibiting IL-17A, secukinumab is used to treat various inflammatory conditions such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1].

According to the Cosentyx (secukinumab) Prescribing Information, "the safety and efficacy of Cosentyx in combination with vaccination have not been studied" [1]. Therefore, it is recommended that patients on immunosuppressive therapy, like Cosentyx, complete their vaccination series before starting the treatment or postpone vaccination until the treatment is completed, depending on the patient's medical condition and the type of vaccine [1].

In summary, while there is no direct evidence that Cosentyx alters vaccine effectiveness at injection points, the drug's immunosuppressive properties may affect the immune system's response to vaccines in general. It is crucial to consult healthcare professionals for personalized advice regarding vaccinations and immunosuppressive therapies [1].

Sources:
[1] Cosentyx (secukinumab) Prescribing Information. Novartis Pharmaceuticals Corporation. <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>